Back to top
more

Phibro Animal Health (PAHC)

(Delayed Data from NSDQ)

$27.33 USD

27.33
183,830

+0.84 (3.17%)

Updated Aug 7, 2025 03:59 PM ET

After-Market: $27.34 +0.01 (0.04%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Phibro Animal Health (PAHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Phibro (PAHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -500% and 1.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Cardinal Health (CAH) in Q4 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) fourth-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.

Zacks Equity Research

Warby Parker Inc. (WRBY) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Warby Parker (WRBY) delivered earnings and revenue surprises of 20% and 0.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zimmer Biomet (ZBH) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 1.52% and 0.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Phibro (PAHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Should You Buy, Sell or Hold McKesson (MCK) Before Q1 Earnings?

by Zacks Equity Research

McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.

Zacks Equity Research

Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?

by Zacks Equity Research

Phibro's (PAHC) Animal Health business, supported by the flourishing Vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.

Zacks Equity Research

Baxter (BAX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) second-quarter results are likely to benefit from positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.

Zacks Equity Research

Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Zacks Equity Research

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Zacks Equity Research

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zacks Value Trader Highlights: Great Lakes Dredge & Dock, HanesBrands, Lands' End, Phibro Animal Health and Wolverine World Wide

by Zacks Equity Research

Great Lakes Dredge & Dock, HanesBrands, Lands' End, Phibro Animal Health and Wolverine World Wide are part of the Zacks Value Trader article.

Tracey Ryniec headshot

How to Invest in Small Cap Value Stocks in 2024

by Tracey Ryniec

Historically, small cap value stocks have been among the best performers. Here's how to screen for them.

Zacks Equity Research

Are Investors Undervaluing National Vision (EYE) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Should Value Investors Buy Baxter International (BAX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Freshpet, AudioEye, Walmart in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Equity Research

Phibro (PAHC) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Phibro (PAHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Phibro (PAHC) Down 3.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Haemonetics Corporation (HAE) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Interpreting Phibro (PAHC) International Revenue Trends

by Zacks Equity Research

Evaluate Phibro's (PAHC) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.